Media Coverage

Back to Media Coverage

Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies

Today Sigilon is announcing a $473 million pact with Eli Lilly — which is stepping out under a bolder R&D chief in Dan Skovronsky — to drive their stem cell work on Type 1 diabetes into the clinic, with $63 million of that in an upfront and the rest divvied up with a goal of fully funding the development of a durable new therapy for the disease.